Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MOMA-341 |
| Synonyms | |
| Therapy Description |
MOMA-341 selectively inhibits WRN, potentially inducing DNA damage and tumor cell death, leading to decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4205). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MOMA-341 | MOMA341|MOMA 341 | WRN Inhibitor 5 | MOMA-341 selectively inhibits WRN, potentially inducing DNA damage and tumor cell death, leading to decreased tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4205). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06974110 | Phase I | Irinotecan + MOMA-341 MOMA-341 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |